||BACKGROUND: Prenyl diphosphate synthase subunit 2 (PDSS2) gene has recently been reported as a potential tumor suppressor. The association of PDSS2 and non-small cell lung cancer (NSCLC) has not been known.
METHODS: To investigate its association with NSCLC, we examined the expression level of PDSS2 in 28 paired clinical samples of non-small cell lung cancer tissues and surrounding normal tissues.
RESULTS: PDSS2 was constitutionally expressed in normal lung tissues regardless of sex, race and smoking history. An overall decreased PDSS2 expression was found in the tumor tissues compared to surrounding normal tissues. Decrease in PDSS2 expression was more severe in poorly and poor-to-moderately differentiated lung cancers, while the decrease was not significant in moderately to well-differentiated tumors. Moreover, the expression of PDSS2 decreased more in higher pathological stage, and in patients with lymph node metastasis. The decrease in PDSS2 expression in tumor tissues was not related to sex or histological type of NSCLC, but was related to smoking history. No correlation has been found between PDSS2 and the clinical factors of EGRF, Ki-67 and p53.
CONCLUSION: Taken together, decreased expression of PDSS2 in NSCLC was evident. This is an initial report for the expression of PDSS2 in relation to different factors in lung cancer. Loss of PDSS2 could serve as a potential biomarker in NSCLC development. The role of PDSS2 as a tumor suppressor, and the mechanism of its potential anti-tumor action in NSCLC warrant further investigation.
Humans; Female; Male; Prognosis; Follow-Up Studies; Reverse Transcriptase Polymerase Chain Reaction; Case-Control Studies; Blotting, Western; RNA, Messenger; Neoplasm Staging; Tumor Markers, Biological; Lymphatic Metastasis; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Adenocarcinoma; Carcinoma, Squamous Cell; Tumor Suppressor Proteins; Lung; Real-Time Polymerase Chain Reaction; Alkyl and Aryl Transferases